Abstract #3061

Hybrid C11 Choline PET/MRI in staging untreated high risk and very high risk prostate cancer patients at single institution: preliminary results

Kelly T Smith¹, Akira Kawashima², Mark D Tyson³, Erik P Castle⁴, Alvin Silva¹, Yuxiang Zhou¹, Michael C Roarke¹, and Ming Yang¹

¹Radiology, Mayo Clinic Arizona, PHOENIX, AZ, United States, ²Radiology, Mayo Clinic Arizona, Phoenix, AZ, United States, ³Urology, Mayo Clinic Arizona, PHOENIX, AZ, United States, ⁴Urology, Mayo Clinic Arizona, Phoenix, AZ, United States

The most prevalent malignancy in US men is prostate cancer. Appropriate treatment regimen is dependent on accurate tumor staging. Pelvic multiparametric MR (mpMRI) is the established modality for tumor and nodal staging. C-11 choline is FDA approved in diagnosis of recurrent prostate cancer. Introduction of a hybrid time-of-flight PET/MR system affords the opportunity to perform a combined C-11 choline PET + mpMRI for prostate cancer staging. We feel this system would be beneficial in staging of treatment naïve high risk prostate cancer.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.